التفاصيل البيبلوغرافية
| العنوان: |
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial |
| المؤلفون: |
Labori, Knut Jørgen, Bratlie, Svein Olav, Andersson, Bodil, Angelsen, Jon-Helge, Biörserud, Christina, Björnsson, Bergthor, Bringeland, Erling Audun, Elander, Nils, Garresori, Herish, Grønbech, Jon Erik, Haux, Johan, Hemmingsson, Oskar, Liljefors, Maria Gustafsson, Myklebust, Tor Åge, Nymo, Linn Såve, Peltola, Katriina, Pfeiffer, Per, Sallinen, Ville, Sandström, Per, Sparrelid, Ernesto, Stenvold, Helge, Søreide, Kjetil, Tingstedt, Bobby, Verbeke, Caroline, Öhlund, Daniel, Klint, Leif, Dueland, Svein, Lassen, Kristoffer, Aahlin, Eirik Kjus, Bratthäll, Charlotte, Halimi, Asif, Hatlevoll, Ingunn, Heby, Margareta, Kokkola, Arto, Kordes, Maximilian, Lindblad, Stina, Lundgren, Linda, Mortensen, Michael Bau, Mortensen, Kim Erlend, Persson, Jan, Rangelova, Elena, Rønne, Elin, Sandvik, Oddvar Mathias, Søreide, Jon Arne, Vilhav, Caroline, Waardal, Kim, Wennerblom, Johanna, Williamsson, Caroline, Yaqub, Sheraz |
| المصدر: |
The Lancet Gastroenterology & Hepatology; March 2024, Vol. 9 Issue: 3 p205-217, 13p |
| مستخلص: |
In patients undergoing resection for pancreatic cancer, adjuvant modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improves overall survival compared with alternative chemotherapy regimens. We aimed to compare the efficacy and safety of neoadjuvant FOLFIRINOX with the standard strategy of upfront surgery in patients with resectable pancreatic ductal adenocarcinoma. |
| قاعدة البيانات: |
Supplemental Index |